

REMARKS

Status Summary

Claims 17-48 are now pending in the subject U.S. patent application. Claims 17-48 have been subjected to a Restriction/Election Requirement.

Applicants have elected the species related to Alzheimer's disease and the species related to compounds of Formula (I).

Claims 23 and 41-43 have been amended by the present amendment. The specification has been amended. No new matter has been added. Therefore, upon entry of the present Amendment, claims 17-48 will be pending in the subject application.

SPECIFICATION AMENDMENTS

The specification has been amended to correct the description of the compounds of Formula (III) at line 24, page 8 to line 19, page 10.

In particular, the structure representing Formula (III) has been amended to replace "C" with "X". Applicants respectfully submit that "C" is being used in Formula (III) as a variable, but that the use of "C" as a variable in the structure may be confusing in that it might be misinterpreted to indicate a carbon atom. Applicants further note that if the "C" in Formula (III) were misinterpreted to be a carbon atom, the structure would be ambiguous in that the "C" carbon atom would not have the proper number of valence electrons. The structure shows only two single bonds to other groups involving "C," and no "C"-associated negative charge.

For clarity, the description of R₃ groups has been moved to follow the complete description of possible R₁ groups.

Further, the description of compounds of Formula (III) has been amended to recite that "X is CH₂O or is a heterocyclic aromatic group..." instead of "A is a heterocyclic aromatic group..." Applicants respectfully submit that the use of the variable "A" in this instance was a typo and that the use of "X" in place of "A" is in keeping with the use of "X" in the structure of Formula

(III) discussed directly above. That "A" is a typo can be supported by the previous description of variable "A" in the description of compounds of Formula (III) at line 1, page 9, which recites that "A and B are each independently selected from the group" Further support for X being a heterocyclic aromatic group can be found in the structures of DB 75, DB 60, DB 181, DB 244, DB 103, DB 351 and DB262 in Table 2 of the specification at pages 25-26. In these compounds, X is a heterocyclic aromatic group, n is zero, R₃ is H, and A and B are as defined on page 9. Support for X being CH₂O can be found in the structures of MC 96, FS 44, FS 104, FS 113, MC 97c, and FS 117 in Table 3 of the specification at pages 26-27. In these compounds, X is CH₂O, n is zero, R₃ is H, and A and B are as defined on page 9.

CLAIM AMENDMENTS

Claims 23 and 41-43 have been amended to correct claim numbering. Applicants note that in the previous Preliminary Amendment, filed December 15, 2005, some of the claims were not numbered in consecutive order as required by 37 CFR 1.126. In particular, two consecutive claims were numbered "22" and no claim was numbered "23". Further, two claims were numbered "40" and no claim was numbered "43". The claims listed following the second claim numbered "40" were numbered "41" and "42" and followed by the correctly numbered claim 44. Accordingly, the claim numbers have been corrected so that the claims are numbered consecutively in the order presented in the previous Preliminary Amendment. Additionally, claim 23 has been amended to depend from claim 22. Claim 41 has been amended to depend from claim 40.

CONCLUSIONS

Should there be any minor issues outstanding in this matter, the Examiner is respectfully requested to telephone the undersigned attorney. Early passage of the subject application to issue is earnestly solicited.

Application Serial No.: 10/663,879


DEPOSIT ACCOUNT

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT P.A.

Date: 9/27/2006

By: 
Arles A. Taylor, Jr.
Registration No. 39,395

421/60/10/2

AAT/ALO/omb

Customer No: 25297